文献速递骨质疏松与钙磷/甲状旁腺

患者管理方法:成人成骨不全症骨折风险降低的药物治疗

Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本文综述成人成骨不全症(OI)骨折风险降低的药物治疗证据。OI 因 I 型胶原结构、合成或翻译后加工缺陷导致骨脆性增加,成人骨折率升高。双膦酸盐和特立帕肽可能改善骨密度,但缺乏确认骨折保护的结论性数据,需进一步研究开发明确降低骨折率的药物。

要点

  • 成人 OI 骨折率升高,但药物治疗降低骨折的证据有限。
  • 口服和静脉双膦酸盐可改善成人 OI 骨密度,但缺乏确认骨折保护的结论性数据。
  • 特立帕肽可能增加骨密度,该效应似乎仅限于 I 型 OI 个体。

核心结论

  • 成人 OI 骨折率升高,尽管临床试验数据有限,双膦酸盐和特立帕肽可能有助于改善骨密度,需进一步研究开发明确降低骨折率的药物。

研究设计与样本

  • 综述,2022 年 6 月在 PubMed 在线数据库检索所有类型的英文研究,检索词为「osteogenesis imperfecta」「OI」和「brittle bone disease」,筛选文章限于成人,并通过手动检索参考文献列表补充来源。

主要发现

  • 口服和静脉双膦酸盐已显示可改善成人 OI 的骨密度且常用,但缺乏确认骨折保护的结论性数据。
  • 特立帕肽似乎增加骨密度,该效应似乎仅限于 I 型 OI 个体。
  • 地舒单抗、阿巴洛肽、罗莫佐单抗和雌二醇/睾酮在成人 OI 中的作用尚未被系统研究。
  • 抗硬化蛋白药物和转化生长因子-β 拮抗剂正在临床试验中研究。

临床怎么用

  • 口服和静脉双膦酸盐已显示可改善成人 OI 的骨密度且常用,但缺乏确认骨折保护的结论性数据。
  • 特立帕肽似乎增加骨密度,该效应似乎仅限于 I 型 OI 个体。
  • 地舒单抗、阿巴洛肽、罗莫佐单抗和雌二醇/睾酮在成人 OI 中的作用尚未被系统研究。

局限性

  • 成人 OI 中用于骨折减少的药物的有效性研究不足,实践建议尚未很好建立。
  • 双膦酸盐缺乏确认骨折保护的结论性数据。
  • 特立帕肽增加骨密度的效应似乎仅限于 I 型 OI 个体。
  • 地舒单抗、阿巴洛肽、罗莫佐单抗和雌二醇/睾酮在成人 OI 中的作用尚未被系统研究。
  • 需进一步研究开发明确降低成人 OI 骨折率的药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone fragility largely caused by defects in structure, synthesis, or post-translational processing of type I collagen. The effectiveness of medications used for fracture reduction in adults with OI is understudied and practice recommendations are not well established. Drugs currently used to improve skeletal health in OI were initially developed to treat osteoporosis. Oral and intravenous bisphosphonates have been shown to improve bone mineral density (BMD) in adults with OI and are commonly used; however, conclusive data confirming fracture protection are lacking. Similarly, teriparatide appears to increase BMD, an effect that seems to be limited to individuals with type I OI. The role of denosumab, abaloparatide, romosozumab, and estradiol/testosterone in adult OI have not been systematically studied. Anti-sclerostin agents and transforming growth factor-beta antagonists are under investigation in clinical trials. OBJECTIVE: This review summarizes current knowledge on pharmacologic treatment options for reducing fracture risk in adults with OI. METHODS: A PubMed online database search of all study types published in the English language using the terms "osteogenesis imperfecta," "OI," and "brittle bone disease" was performed in June 2022. Articles screened were restricted to adults. Additional sources were identified through manual searches of reference lists. CONCLUSION: Fracture rates are elevated in adults with OI. Although clinical trial data are limited, bisphosphonates and teriparatide may be useful in improving BMD. Further research is needed to develop medications for adults with OI that will lead to definite fracture rate reduction.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu W, Lee B, Nagamani SCS, et al. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023. PMID: 36658750. doi:10.1210/clinem/dgad035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。